US8450344 — Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Method of Use · Assigned to Aerie Pharmaceuticals Inc · Expires 2026-07-11 · 0y remaining
What this patent protects
This patent protects beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds useful as therapeutic agents for treating various diseases and conditions.
USPTO Abstract
Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
Drugs covered by this patent
- Xalatan (LATANOPROST) · Thea Pharma
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1524 |
— | |
U-1524 |
— | Xalatan |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.